Analysemethode:
Particle-enhanced turbidimetric inhibition immunoassay technique op Atellica, Siemens Healthineers.
Deelname EKE:
LGC Therapeutic Drugs Monitoring Scheme: PT-TM-TD1
Interferentie:
100 µg/mL 5-Hydroxy valproaat: veroorzaakt 28% kruisreactiviteit; 100 µg/mL 4-ene valproic acid veroorzaakt 47% kruisreactiviteit.